CONMED Corporation
CNMD · Price history
Price at last available close
$45.72
−$0.51 (-1.10%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About CONMED Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations.
How they make money
CONMED Corporation is a medical technology company that generates revenue by developing, manufacturing, and selling surgical devices and equipment for minimally invasive procedures. The company utilizes a direct sales force and medical specialty distributors to sell its products to hospitals, surgery centers, and other healthcare institutions globally.
Products & services
The company provides powered resection instruments, fluid management and visualization systems, and related single-use surgical products.
Brands & revenue mix
Brand for surgical devices and equipment.
Separate brand revenue is not available in this research.Source
Brand for surgical devices and equipment.
Separate brand revenue is not available in this research.Source
Brand for surgical devices and equipment.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
The company is not dependent on any single customer, and no single customer accounted for more than 10% of net sales in 2025.
Suppliers, materials & equipment
- Contract manufacturers and raw material suppliers — The company relies on various third-party suppliers for raw materials, components, and contract manufacturing services to support its production operations.Source
Strengths
- Broad portfolio of single-use and capital smoke evacuation productsSource
Risks
- Dependence on technological advances and market changesSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
39
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
54
Fair
Financial Strength
71
Business Quality / Moat
65
Management
41
Growth Quality
26
Risk / Durability
42
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
48
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
49/100
Building Historical Record
Model Score 49/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CNMD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving CNMD's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is CNMD's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is CNMD's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify CNMD's current valuation?
Essential Investment Snapshot
Wall Street Score
39
Opportunity Score
48
Market Cap
$1.37B
P/E Ratio
25.0
EPS
$1.85
52-Week High
$53.66
52-Week Low
$31.44
Beta
0.91
Intrinsic Value
$51.12
Analyst Target
$37.50
Shares Outstanding
31.1M
Total Revenue
$1.37B
Total Debt
$834.2M
Dividend
No current dividend
Liquidation Value / Share
$33.43
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CNMD
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Community Sentiment
0 active · 0 total callsNo personal call yet on CNMD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Broad portfolio of single-use and capital smoke evacuation products.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on technological advances and market changes.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
38
Sep 17, 2026
Change
+0.7
points
Current Score
39
Oct 1, 2026
Category Changes
CNMD increased 0.7 points because Valuation improved by 2.8 points.
Positive Contributors
- + Valuation improved by 2.8 points
Projected Score
Projected Score
44
Projected Change
+5.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$45.72
Model Intrinsic Value
$51.12
Difference
−$5.40
-10.6% vs IV
Margin of Safety
10.6%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.37B | $1.31B | $1.24B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $620.4M | $649.1M | $574.0M | $568.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $752.2M | $725.4M | $733.0M | $676.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $60.6M | $55.9M | $54.4M | $52.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $543.5M | $528.4M | $478.3M | $503.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $604.1M | $584.2M | $532.7M | $555.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $180.0M | $154.5M | $272.2M | $192.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $148.1M | $141.1M | $200.3M | $120.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $29.9M | $31.1M | $37.3M | $39.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $83.2M | $71.1M | $163.0M | $80.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $26.7M | $24.1M | $30.6M | $16.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $56.5M | $47.1M | $132.4M | $64.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $1.85 | $1.52 | $4.29 | $2.10 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 30.07M | 31.04M | 30.85M | 30.67M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 30.12M | 31.15M | 31.11M | 31.55M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$343.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.77
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-5.4%
Cash Change
+10.0%
Margin Change
+0.5 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 0.1%. EPS increased 11.6%. Cash increased 10.0%. Total debt declined 5.4%. Net income margin improved by 0.5 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Canada Pension Plan Investment Board Buys Shares of 13,800 CONMED Corporation $CNMD
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
Rumor Mill · CNMD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial